9 Meters Biopharma

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. The company is founded by Jay P. Madan and Kendyle Woodard in 2012 and is headquartered in Raleigh, NC.

New York Mortgage Trust, Inc. is a real estate investment trust, which engages in the acquisition, investment, finance, and management of mortgage-related single-family and multi-family residential assets. Its investment portfolio includes credit sensitive single-family and multi-family assets. The company was founded on September 26, 2003 and is headquartered in New York, NY.

Senmiao Technology

Diffusion Pharmaceuticals

Ault Global Holdings

Harmony Gold Mining Co Ltd

iBio

Tellurian

Are these trending penny stocks worth adding to your watchlist? The post 7 Trending Penny Stocks That You Need to Know About in July 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Trending Penny Stocks That You Need to Know About in July 2021

RALEIGH, NC / ACCESSWIRE / June 28, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage biotechnology company focused on rare and unmet needs in gastroenterology, announced today it has joined the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell U.S. Indexes annual reconstitution. These updated Indexes will become effective after U.S. equity markets open today, Monday June 28, 2021.

9 Meters Added to Russell 2000(R) and 3000(R) Indexes

Initiating the largest Phase 2 placebo-controlled trial in short bowel syndrome Topline results of the multicenter VIBRANT study anticipated in Q4 2021 RALEIGH, NC / ACCESSWIRE / June 14, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage biotechnology company focused on rare and unmet needs in gastroenterology, announced today the initiation of its Phase 2 trial of vurolenatide, a proprietary long-acting glucagon-like peptide-1 (GLP-1) agonist in adults with short bowel syndrome (SBS). "Initiating our Phase 2 trial of vurolenatide marks an important milestone for patients and families impacted by the debilitating effects of short bowel syndrome, including chronic diarrhea," said John Temperato, President and Chief Executive Officer of 9 Meters.

9 Meters Announces Initiation of Phase 2 VIBRANT Study of Vurolenatide for Short Bowel Syndrome

RALEIGH, NC / ACCESSWIRE / June 9, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO of 9 Meters Biopharma will deliver a company presentation at 2021 BIO Digital being held June 10-11 & 14-18, 2021. 9 Meters invites investors to participate in live meetings on the BIO One-on-One Partnering™ system which will begin on June 14th.

9 Meters Biopharma, Inc. to Present at 2021 BIO Digital

RALEIGH, NC / ACCESSWIRE / June 1, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO of 9 Meters Biopharma will present at the Jefferies Virtual Healthcare Conference being held June 1- 4, 2021 and invites investors to participate via webcast and in one-on-one meetings. The presentation will be followed by a virtual Q&A session.

9 Meters Biopharma, Inc. to Present at the Jefferies Virtual Healthcare Conference

- Larazotide supplied to study authors under an FDA-approved Expanded Access Program - - Treatment showed a dramatic drop in inflammatory mediators leading to clinical stabilization, providing proof-of-concept support for larazotide's mechanism of action - RALEIGH, NC / ACCESSWIRE / May 26, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced the publication of an article in the Journal of Clinical Investigation demonstrating the use of larazotide in successfully treating a 17-month infant with multisystem inflammatory syndrome in children (MIS-C). Larazotide is a novel first-in-class tight junction regulator currently in Phase 3 clinical development for adults with celiac disease.

9 Meters Biopharma, Inc. Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children (MIS-C) resulting from COVID-19 Infection

Investors need to pay close attention to 9 Meters Biopharma (NMTR) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in 9 Meters Biopharma (NMTR) Stock?

This version of the release contains a corrected hyperlink. RALEIGH, NC / ACCESSWIRE / May 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company's CEO, John Temperato will present a corporate update at Oppenheimer's Rare & Orphan Disease Summit and invites investors to participate via webcast and in one-on-one meetings.

CORRECTION 9 Meters Biopharma, Inc. to Present at Oppenheimer's Rare & Orphan Disease Summit

RALEIGH, NC / ACCESSWIRE / May 18, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company's CEO, John Temperato will present a corporate update at Oppenheimer's Rare & Orphan Disease Summit and invites investors to participate via webcast and in one-on-one meetings. Please see additional details below: Oppenheimer's Rare & Orphan Disease Summit Date: May 21, 2021 Time: 3:45 - 4:25 p.m.

9 Meters Biopharma, Inc. to Present at Oppenheimer's Rare & Orphan Disease Summit

RALEIGH, NC / ACCESSWIRE / May 17, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage biotechnology company focused on rare and unmet needs in gastroenterology, announced today that the United States Adopted Names (USAN) Council has officially designated the Company's long-acting injectable glucagon-like peptide-1 (GLP-1) receptor agonist drug candidate for short bowel syndrome, NM-002, as "vurolenatide." "Unlike other agents in development for short bowel syndrome, vurolenatide is distinct not only from other GLP-1 agonists, but especially from GLP-2 agonists.

9 Meters Biopharma, Inc. Receives USAN Approval to Use the Designated Nonproprietary Name Vurolenatide for Its Long-Acting GLP-1 Agonist for Short Bowel Syndrome

- Company Closed a $31.5M equity offering in April 2021; provides cash runway into 2023 - Plan to initiate Phase 2 trial with NM-002 in SBS with total stool output as the primary endpoint in Q2 following FDA guidance - Announced a collaboration with the Celiac Disease Foundation (CDF) to support clinical trial enrollment in 9 Meters' Phase 3 study, CeDLara, for larazotide in celiac disease RALEIGH, NC / ACCESSWIRE / May 13, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today provided an overview of its recent achievements and reported its financial results for the first quarter ended March 31, 2021. Key Business Highlights In April, the Company closed a public offering of 34.5 million shares of common stock, inclusive of the full overallotment option exercised by the underwriters.

9 Meters Biopharma Provides Business Update and Reports Financial Results for the First Quarter 2021

RALEIGH, NC / ACCESSWIRE / April 21, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that management will participate in the 7th Annual Truist Securities Life Sciences Summit and invites investors to participate in one-on-one meetings. Please see additional details below: Truist Securities 7th Annual Life Sciences Summit Date: May 4 - 5, 2021 Participation: Management will be available for 1-on-1 meetings virtually Please contact your representative at Truist Securities to schedule a virtual one-on-one meeting with 9 Meters during the respective conference.

9 Meters Biopharma, Inc. to Participate in the Truist Securities 7th Annual Life Sciences Summit

22nd Century Group

Liquid Media Group Ltd

Penny stocks continue to trend; which should you add to your watchlist? The post 3 Penny Stocks For Your ‘Doge Day' Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks For Your ‘Doge Day' Watchlist

RALEIGH, NC / ACCESSWIRE / April 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that the Company will enter into a collaboration with the Duke Clinical Research Institute (DCRI) to support the clinical development of 9 Meters' candidate NM-002, a proprietary long-acting GLP-1 agonist, currently in Phase 2 development for short bowel syndrome (SBS). SBS is a life-threatening orphan disease caused by a significant shortening of the gastrointestinal tract, leading to impaired nutrient absorption.

9 Meters Biopharma, Inc. Announces Collaboration with the Duke Clinical Research Institute to Support 9 Meters' Program in Short Bowel Syndrome

RALEIGH, NC / ACCESSWIRE / April 12, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that the Company will collaborate with the Celiac Disease Foundation (CDF) to support clinical trial enrollment in 9 Meters' Phase 3 study, CeDLara, for their drug candidate larazotide in celiac disease. 9 Meters' CeDLara study is a Phase 3 randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of 9 Meters' investigational drug, larazotide, for adult patients with at least a six-month history of celiac disease who continue to experience gastrointestinal symptoms despite maintaining a gluten-free diet for at least six months.

9 Meters Biopharma, Inc. and Celiac Disease Foundation Announce Collaboration to Support Clinical Trial Enrollment in 9 Meters' Phase 3 CeDLara Study

Some of the company's executives are making notable moves.

Why 9 Meters Biopharma Stock Is Soaring Today

The stock price of 9 Meters Biopharma Inc (NASDAQ: NMTR) increased by over 10% pre-market. This is why it happened.

9 Meters Biopharma Stock Price Increased Over 10% Pre-Market: Why It Happened

RALEIGH, NC / ACCESSWIRE / April 5, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today the closing of its previously announced underwritten public offering of 34,500,000 shares of its common stock, inclusive of the full overallotment option exercised by the underwriters, at a price to the public of $1.00 per share. The net proceeds to the Company from the public offering, after deducting underwriting discounts and commissions and offering expenses payable by 9 Meters, were approximately $31.5 million.

9 Meters Biopharma Announces Closing of Offering of Common Stock

The stock price of 9 Meters Biopharma, Inc. (NASDAQ:NMTR) fell by over 20% pre-market. This is why it happened.

NMTR Stock Price Fell Over 20% Pre-Market: Why It Happened

RALEIGH, NC / ACCESSWIRE / March 30, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today the pricing of an underwritten public offering of 30,000,000 shares of its common stock at a price to the public of $1.00 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to 4,500,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions.

9 Meters Biopharma Prices Public Offering of Common Stock

RALEIGH, NC / ACCESSWIRE / March 30, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that it has commenced a proposed underwritten public offering of shares of its common stock. In connection with this offering, 9 Meters Biopharma expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock to be sold in the offering.

9 Meters Biopharma Announces Proposed Public Offering of Common Stock

FDA Type C meeting communications support plans to initiate Phase 2 in Q2 with NM-002 for short bowel syndrome (SBS) using Total Stool Output (TSO) as a primary efficacy outcome measure  Announced positive topline data in December for NM-002, a proprietary long-acting GLP-1, in a Phase 1b/2a trial for SBS  Company's R&D day on March 23rd to include additional Phase 1b/2a study data on parenteral support, pharmacokinetics and quality of life  Phase 3 interim analysis and topline data for larazotide in celiac disease now anticipated in 2022 due to COVID-19 impact on patient enrollment  Raised over $58 million from prominent institutional healthcare investors in 2020  Research & Development Day on Short Bowel Syndrome planned for tomorrow (March 23rd) at 11:00 AM ET - see https://media.rampard.com/20210323/reg.jsp for registration details RALEIGH, NC / ACCESSWIRE / March 22, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today provided an overview of its recent achievements and 2021 outlook and reported its financial results for the fourth quarter and full year ended December 31, 2020. Full Year & Recent Business Highlights After a recent productive FDA interaction in Q1 2021, the Company plans to move forward using total stool output (TSO) as the primary efficacy endpoint in an upcoming Phase 2 trial, which we plan to begin in Q2 and report final data in Q4.

9 Meters Biopharma Provides Business Update and Reports Financial Results for the Fourth Quarter and Full Year 2020

Tuesday, March 23rd @ 11am Eastern Time RALEIGH, NC / ACCESSWIRE / March 15, 2021 / 9 Meters Biopharma (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced that it will host a key opinion leader (KOL) webinar on short bowel syndrome (SBS) and provide an update on the NM-002 (proprietary GLP-1 agonist) development program on Tuesday, March 23, 2021 at 11am Eastern Time. The webinar will feature presentations by KOLs Carol Rees Parrish, M.S.

9 Meters Biopharma Hosting Key Opinion Leader Webinar on Short Bowel Syndrome and NM-002 Program Update

- Oppenheimer 31st Annual Healthcare Conference - March 16th - 18th - Maxim Group 2021 Emerging Growth Virtual Conference - March 17th - 18th RALEIGH, NC / ACCESSWIRE / March 10, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced that management will participate in the following conferences in the month of March and invites investors to participate by webcast or one-on-one meetings. Please see additional details below: Oppenheimer 31st Annual Healthcare Conference Title: 9 Meters Biopharma (NMTR) Company Presentation Date: Wednesday, March 17, 2021 Time: 8:00 - 8:30 AM (ET) Presenter: John Temperato, President & CEO M Vest and Maxim Group 2021 Emerging Growth Virtual Conference Title: 9 Meters Biopharma (NMTR) Date: On demand presentation Presenter: John Temperato, President & CEO If you are interested in arranging a one-on-one meeting, please contact your bank conference representative or contact Corey Davis at LifeSciAdvisors.

9 Meters Biopharma, Inc. to Participate in the following Virtual March Investor Conferences

RALEIGH, NC / ACCESSWIRE / March 9, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, announced today that chief medical officer Patrick Griffin, M.D., FACP, will participate in an invited presentation at an upcoming virtual workshop entitled Accelerating Progress in Celiac Disease.

News for 9 Meters Biopharma Stock (NMTR)